|
Aug 11, 2026
|
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
|
|
|
Aug 05, 2026
|
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
|
|
|
Jun 18, 2026
|
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
|
|
|
Jun 16, 2026
|
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
|
|
|
Jun 01, 2026
|
Innoviva to Participate in Upcoming Investor Conferences
|
|
|
May 06, 2026
|
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
|
|
|
Feb 25, 2026
|
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
|
|
|
Feb 19, 2026
|
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
|
|